A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Trial Profile

A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs CMB 305 (Primary) ; Atezolizumab
  • Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Immune Design
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed from 1 Jul 2019 to 1 Mar 2019.
    • 26 Jun 2018 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
    • 01 Nov 2017 According to an Immune Design media release, data from the study will be presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top